Category: Joint ventures/collaborations
-
Cancer Labs Crowdsource Drug Discovery
3 September 2015. Ontario Institute for Cancer Research and Structural Genomics Consortium are making an early-stage drug prototype freely available to the biomedical research community to further define its therapeutic capabilities. Financial and intellectual property aspects of the offer were not immediately disclosed. The two research labs — both in Toronto, Ontario, Canada — jointly…
-
Sanofi, Google to Partner on Diabetes Care, Devices
31 August 2015. The pharmaceutical company Sanofi is collaborating with Google’s life sciences teams to develop technologies for improving the care of people with diabetes. Financial and intellectual property details of the partnership were not disclosed. Diabetes is a chronic condition where the pancreas does not create enough insulin to process the sugar glucose to flow…
-
Allied-Bristol Licensing Immunotherapy Technology
27 August 2015. Allied-Bristol Life Sciences, a joint venture of science commercialization company Allied Minds and Bristol-Myers Squibb, is licensing a new type of synthetic chemistry technology from Yale University that can stimulate the immune system to treat cancer. Financial details of the licensing agreement were not disclosed. The agreement covers a technology known as…
-
Pharma, Research Group Partner on Meningitis Therapy
26 August 2016. A collaboration between a company developing anti-fungal drugs and research group specializing in fungal infections aims to advance a new type of therapy for cryptococcal meningitis, a life-threatening infection affecting the brain and spinal cord. Financial details of the partnership between Viamet Pharmaceuticals in Research Triangle Park, North Carolina and Mycoses Study Group Education and Research Consortium in Birmingham,…
-
Flatiron, Guardant Partner on Cancer Genomics, Analytics
19 August 2015. Guardant Health, a provider of genomic analysis from liquid biopsies, and Flatiron Health, a provider of electronic records and analytics for cancer patients are collaborating on a cloud-based platform to support research leading to targeted therapies for cancer patients. The companies expect the service to be available in the first half of…
-
NSF Funds Math Tutoring Software Commercialization
18 August 2015. Software to help primary and secondary school students learn mathematics is receiving financial support from National Science Foundation to bring the software to market. NSF awarded a grant of nearly $200,000 to Beverly Woolf, a computer scientist at University of Massachusetts in Amherst, for the 18-month project. Woolf is developer of the…
-
Intrexon Acquires Oxitec, Partners on Genetic Disorder
10 August 2015. Intrexon Corp., a biotechnology company specializing in synthetic biology, is acquiring Oxitec Ltd., a designer of genetically modified insects to control the spread of disease-bearing and agricultural pests for $160 million. Intrexon is also partnering with Synthetic Biologics Inc. to develop therapies for phenylketonuria, a genetic metabolic disorder. Intrexon, in Gaithersburg, Maryland…
-
Research, Finance Alliance to Fast-Track Alzheimer’s Drugs
24 July 2015. A coalition of research institute, venture capital firm, and drug discovery company is forming a new enterprise to develop therapy candidates for Alzheimer’s disease from promising lab results. Financial terms of the partnership of Gladstone Institutes and Dolby Family Ventures in San Francisco with Evotec AG in Hamburg, Germany were not disclosed.…
-
Alliance to Collect Mobile Health Data for Clinical Trials
21 July 2015. A partnership between health technology companies developing cloud-based solutions aims to make it easier to collect data from a wide range of mobile apps for clinical studies. Financial aspects of the agreement between digital health platform company Validic and clinical research technology company Medidata were not disclosed. Validic, in Durham, North Carolina,…
-
Trial Shows Engineered T-Cells Act on Multiple Myeloma
21 July 2015. An early-stage clinical trial shows immune system cells from patients with the blood-related cancer multiple myeloma — modified to attack a protein suspected of helping the cancer grow — generated a positive clinical response in most of the participants. The team from University of Pennsylvania cancer center, University of Maryland medical school,…